These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25943859)

  • 1. Short-term cost analysis of complications related to glycated hemoglobin in patients with type 1 diabetes in the Italian setting.
    Nicolucci A; Buseghin G; De Portu S
    Acta Diabetol; 2016 Apr; 53(2):199-204. PubMed ID: 25943859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):911-915. PubMed ID: 30082172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the UK.
    Choudhary P; de Portu S; Delbaere A; Lyon J; Pickup JC
    Diabet Med; 2019 Aug; 36(8):988-994. PubMed ID: 30710449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.
    Bansal M; Shah M; Reilly B; Willman S; Gill M; Kaufman FR
    Appl Health Econ Health Policy; 2018 Oct; 16(5):675-684. PubMed ID: 29936685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications.
    Stern Z; Levy R
    Acta Diabetol; 1996 Mar; 33(1):48-52. PubMed ID: 8777285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK.
    Bain SC; Bekker Hansen B; Hunt B; Chubb B; Valentine WJ
    J Med Econ; 2020 Jan; 23(1):98-105. PubMed ID: 31311364
    [No Abstract]   [Full Text] [Related]  

  • 7. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.
    International Expert Committee
    Diabetes Care; 2009 Jul; 32(7):1327-34. PubMed ID: 19502545
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life.
    Wu SY; Sainfort F; Tomar RH; Tollios JL; Fryback DG; Klein R; Klein BE
    Diabetes Care; 1998 May; 21(5):725-31. PubMed ID: 9589231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.
    Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.
    Kilpatrick ES; Rigby AS; Atkin SL
    Diabetes Care; 2008 Nov; 31(11):2198-202. PubMed ID: 18650371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
    O'Brien JA; Patrick AR; Caro JJ
    BMC Health Serv Res; 2003 Mar; 3(1):7. PubMed ID: 12659641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.
    Genuth S
    Endocr Pract; 2006; 12 Suppl 1():34-41. PubMed ID: 16627378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a cost-utility model for Type 1 diabetes mellitus.
    Wolowacz S; Pearson I; Shannon P; Chubb B; Gundgaard J; Davies M; Briggs A
    Diabet Med; 2015 Aug; 32(8):1023-35. PubMed ID: 25484028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model.
    Tomar RH; Lee S; Wu SY; Klein R; Klein BE; Moss SE; Fryback DG; Tollios JL; Sainfort F
    J Soc Health Syst; 1998; 5(4):24-37. PubMed ID: 9785295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran.
    Molla GJ; Ismail-Beigi F; Larijani B; Khaloo P; Moosaie F; Alemi H; Mansournia MA; Ghadimi T; Ghaemi F; Nakhjavani M; Esteghamati A
    Can J Diabetes; 2020 Apr; 44(3):246-252. PubMed ID: 31494031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Metabolic Control and Diabetes Management in Insulin-Treated Patients Results in Substantial Cost Savings for the German Health System.
    Fritzen K; Gutschek B; Coucke B; Zakrzewska K; Hummel M; Schnell O
    J Diabetes Sci Technol; 2018 Sep; 12(5):1002-1006. PubMed ID: 29436251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.
    Thomas A; Heinemann L
    J Diabetes Sci Technol; 2012 May; 6(3):572-80. PubMed ID: 22768888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.